Prevention of excessive endothelin-1 release in sclerotherapy: in vitro and in vivo studies.
Dermatol Surg
; 40(7): 769-75, 2014 Jul.
Article
em En
| MEDLINE
| ID: mdl-25111350
ABSTRACT
BACKGROUND:
The foam sclerotherapy technique has become one of the most commonly used treatments for superficial venous insufficiency. Despite excellent results, few visual/neurologic disturbances have been recently reported; their pathogenesis is still debated but a correlation with endothelin-1 (ET-1) release from the treated vein has been proposed.OBJECTIVE:
The purpose of this work was to evaluate the ET-1 release after sclerotherapy and to investigate the effects of the anti-endothelin drug aminaphtone. METHODS AND MATERIALS As in vitro sclerotherapy model, an endothelial cell culture, mimicking vascular endothelium, was pretreated with aminaphtone and exposed to detergents. Cell survival and ET-1 release were measured. In in vivo experiments, 45 rats, fed with different aminaphtone-rich diets, were subjected to sclerotherapy, and the systemic ET-1 was measured.RESULTS:
Aminaphtone cell exposure caused a statistically significant reduction in ET-1 release, both before and after in vitro sclerotherapy. Rats fed with aminaphtone showed a trend toward reduced mortality and a significant decrease of ET-1 release after sclerotherapy.CONCLUSION:
This is the first study in which an anti-endothelin agent was able to cause a significant reduction of ET-1 release during sclerotherapy. Although clinical studies are required, these findings might advocate the use of anti-endothelin agents in prophylaxis of neurologic or visual disturbances after sclerotherapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Soluções Esclerosantes
/
Hemostáticos
/
Escleroterapia
/
Endotelina-1
/
Células Endoteliais da Veia Umbilical Humana
/
Para-Aminobenzoatos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article